We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Implantable Device for Pulmonary Hypertension Reduces Cardiac Workload and Enhances Blood Flow

By HospiMedica International staff writers
Posted on 04 Mar 2024

Pulmonary hypertension is a severe, progressive disease affecting as many as 70 million people globally. More...

It develops when the walls of the pulmonary arteries become rigid, losing their ability to stretch adequately to manage blood flow. Normally, the pressure in the pulmonary arteries of a healthy individual is relatively low. However, in patients with pulmonary hypertension, this pressure increases, and the vessel walls thicken and narrow, impeding blood flow and diminishing vessel elasticity with each heartbeat. This leads to heightened pressure and additional strain on the right side of the heart. Now, a novel implantable device can mimic the function of the healthy vessels by restoring compliance to the pulmonary vessels, thus enabling the heart to pump more blood for less energy. These can improve the ability to exercise while reducing the burden on the heart.

Aria CV’s (St. Paul, MN, USA) Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously and functions in the main pulmonary artery to reduce the excessive workload on the right heart that can cause right heart failure. The device aims to restore the benefits of a healthy pulmonary artery by reducing cardiac workload and increasing blood flow through the lungs. This novel device offers an alternative treatment for patients who continue to be significantly impacted by right heart dysfunction related to pulmonary hypertension, for which there are limited approved therapy options. The first patient has now been successfully implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial. The ASPIRE PH trial is a feasibility study assessing the initial safety, tolerability, and efficacy of the Aria System under the Food and Drug Administration’s (FDA) Early Feasibility Study Program.

“The successful patient implant of the Gen 2 system is a significant milestone in realizing our mission to improve the lives of those suffering from pulmonary hypertension, a life-threatening disease that can lead to heart failure,” said Dan Gladney, President and CEO of Aria CV. “This procedure is a testament to the dedicated ASPIRE PH team that is providing patients with a novel therapeutic option to treat this deadly condition. If approved, this technology has the potential to be lifesaving and life-changing for thousands of patients with pulmonary hypertension.”


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
Dual-Screen Medical Display
C822W
New
Medical Cart
Medical Carts
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.